Eculizumab Substantially Reduces Myasthenia Gravis Events

(MedPage Today) -- PHOENIX – Generalized myasthenia gravis patients had dramatically lower incidence of flares and crises after starting on the complement component 5 inhibitor eculizumab (Soliris), data from a real-world registry showed...
Source: MedPage Today Neurology - Category: Neurology Source Type: news